JP2025511187A - Cd3結合タンパク質及びその使用方法 - Google Patents

Cd3結合タンパク質及びその使用方法 Download PDF

Info

Publication number
JP2025511187A
JP2025511187A JP2024558023A JP2024558023A JP2025511187A JP 2025511187 A JP2025511187 A JP 2025511187A JP 2024558023 A JP2024558023 A JP 2024558023A JP 2024558023 A JP2024558023 A JP 2024558023A JP 2025511187 A JP2025511187 A JP 2025511187A
Authority
JP
Japan
Prior art keywords
seq
target binding
binding protein
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511187A5 (cg-RX-API-DMAC7.html
Inventor
マダン エム. ペイドゥンガット,
サヤンタン ミトラ,
レイラ エム. バウスタニー,
エレイン アン マリアーノ フォックス,
トラン ティー.ティー. ヴー,
ローリー ウォン,
ヴィーナ ヴィノード,
ニコル ジー. ラプヤデ,
メリッサ トリュー,
ヴィジット ダラル,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of JP2025511187A publication Critical patent/JP2025511187A/ja
Priority to JP2026057622A priority Critical patent/JP2026099821A/ja
Publication of JP2025511187A5 publication Critical patent/JP2025511187A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024558023A 2022-04-01 2023-03-31 Cd3結合タンパク質及びその使用方法 Pending JP2025511187A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026057622A JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326668P 2022-04-01 2022-04-01
US63/326,668 2022-04-01
PCT/US2023/017130 WO2023192606A2 (en) 2022-04-01 2023-03-31 Cd3-binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026057622A Division JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Publications (2)

Publication Number Publication Date
JP2025511187A true JP2025511187A (ja) 2025-04-15
JP2025511187A5 JP2025511187A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=86185147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024558023A Pending JP2025511187A (ja) 2022-04-01 2023-03-31 Cd3結合タンパク質及びその使用方法
JP2026057622A Pending JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026057622A Pending JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Country Status (5)

Country Link
US (1) US20250230239A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504782A2 (cg-RX-API-DMAC7.html)
JP (2) JP2025511187A (cg-RX-API-DMAC7.html)
CN (1) CN119278215A (cg-RX-API-DMAC7.html)
WO (1) WO2023192606A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス,インコーポレイテッド 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
CN111212853A (zh) 2017-08-30 2020-05-29 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20200405890A1 (en) 2018-02-21 2020-12-31 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
KR20200142525A (ko) * 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
BR112021008526A2 (pt) 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
WO2020236679A1 (en) 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
US20220306745A1 (en) 2019-06-13 2022-09-29 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
WO2020252358A1 (en) 2019-06-13 2020-12-17 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
EP4034171A1 (en) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥(上海)有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
AU2021206218A1 (en) 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods

Also Published As

Publication number Publication date
EP4504782A2 (en) 2025-02-12
US20250230239A1 (en) 2025-07-17
CN119278215A (zh) 2025-01-07
JP2026099821A (ja) 2026-06-18
WO2023192606A2 (en) 2023-10-05
WO2023192606A3 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP2022066565A (ja) 抗ntb-a抗体ならびに関連する組成物および方法
US12551571B2 (en) Protease-cleavable substrates and methods of use thereof
US20260049148A1 (en) Protease-cleavable moieties and methods of use thereof
US12617856B2 (en) Protease-cleavable substrates and methods of use thereof
JP2016538242A (ja) 二重特異性ナノボディ
CN104936621A (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
CN107207564A (zh) 靶向xten缀合物组合物及其制备方法
AU2015292406A1 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
JP2025525880A (ja) プロテアーゼ切断性部分及びその使用方法
JP2025525868A (ja) プロテアーゼ切断性部分及びその使用方法
JP2021515542A (ja) Pd1結合剤
CN114746115A (zh) 抗原结合蛋白构建体及其用途
JP2025512798A (ja) 活性化可能な二重アンカー型マスク化分子及びその使用方法
JP2021515544A (ja) Erbb3結合剤
EP4504782A2 (en) Cd3-binding proteins and methods of use thereof
CN120053680A (zh) 抗原结合蛋白构建体及其用途
JP2025511190A (ja) 活性化可能な多重特異性分子及びその使用方法
JP2024538042A (ja) 三量体活性化可能サイトカイン構成体ならびに関連する組成物及び方法
US12545731B2 (en) Single-and multi-chain polypeptides that bind specifically to CD3 epsilon
WO2026035650A2 (en) Cleavable polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260331